Samarth Kulkarni

2020

In 2020, Samarth Kulkarni earned a total compensation of $9.1M as Chief Executive Officer at CRISPR Therapeutics AG, a 44% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$543,750
Option Awards$6,343,596
Salary$625,000
Stock Awards$1,585,785
Other$7,125
Total$9,105,256

Kulkarni received $6.3M in option awards, accounting for 70% of the total pay in 2020.

Kulkarni also received $543.8K in non-equity incentive plan, $625K in salary, $1.6M in stock awards and $7.1K in other compensation.

Rankings

In 2020, Samarth Kulkarni's compensation ranked 970th out of 13,090 executives tracked by ExecPay. In other words, Kulkarni earned more than 92.6% of executives.

ClassificationRankingPercentile
All
970
out of 13,090
93rd
Division
Manufacturing
341
out of 5,618
94th
Major group
Chemicals And Allied Products
116
out of 2,251
95th
Industry group
Drugs
102
out of 1,951
95th
Industry
Biological Products, Except Diagnostic Substances
26
out of 411
94th
Source: SEC filing on April 28, 2021.

Kulkarni's colleagues

We found four more compensation records of executives who worked with Samarth Kulkarni at CRISPR Therapeutics AG in 2020.

2020

Tony Ho

CRISPR Therapeutics AG

EVP, Research and Development

2020

Lawrence Klein

CRISPR Therapeutics AG

Chief Operating Officer

2020

Michael Tomsicek

CRISPR Therapeutics AG

Chief Financial Officer

2020

James Kasinger

CRISPR Therapeutics AG

General Counsel

News

In-depth

You may also like